CASI Pharmaceuticals (CASIF) Total Non-Current Liabilities (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Total Non-Current Liabilities data on file, last reported at $49.7 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 36.26% year-over-year to $49.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $49.7 million (up 36.26% YoY) and the FY2025 annual result came in at $49.7 million, up 36.26% from the prior year.
• Total Non-Current Liabilities rose to $49.7 million in Q4 2025, from $39.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $49.7 million in Q4 2025 to a low of -$15.4 billion in Q4 2023.
• A 5-year average of -$5.2 billion and a median of $17.0 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 90843.29% — and 2025, when it soared 100.27%.
• Tracing CASIF's Total Non-Current Liabilities over 5 years: stood at $16.0 million in 2021, then climbed by 6.19% to $17.0 million in 2022, then tumbled by 90843.29% to -$15.4 billion in 2023, then soared by 100.24% to $36.5 million in 2024, then soared by 36.26% to $49.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $49.7 million (Q4 2025), $39.4 million (Q3 2025), and $37.7 million (Q2 2025), per Business Quant data.